These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 14751030)
1. Modulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by chemotherapy in thyroid cancer cell lines. Park JW; Wong MG; Lobo M; Hyun WC; Duh QY; Clark OH Thyroid; 2003 Dec; 13(12):1103-10. PubMed ID: 14751030 [TBL] [Abstract][Full Text] [Related]
2. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279 [TBL] [Abstract][Full Text] [Related]
3. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention. Ahmad M; Shi Y Oncogene; 2000 Jul; 19(30):3363-71. PubMed ID: 10918593 [TBL] [Abstract][Full Text] [Related]
4. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2. Munshi A; Pappas G; Honda T; McDonnell TJ; Younes A; Li Y; Meyn RE Oncogene; 2001 Jun; 20(29):3757-65. PubMed ID: 11439339 [TBL] [Abstract][Full Text] [Related]
5. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells. Cuello M; Ettenberg SA; Nau MM; Lipkowitz S Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126 [TBL] [Abstract][Full Text] [Related]
6. Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP. Mühlethaler-Mottet A; Bourloud KB; Auderset K; Joseph JM; Gross N Oncogene; 2004 Jul; 23(32):5415-25. PubMed ID: 15094781 [TBL] [Abstract][Full Text] [Related]
7. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand. Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619 [TBL] [Abstract][Full Text] [Related]
8. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Singh TR; Shankar S; Chen X; Asim M; Srivastava RK Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373 [TBL] [Abstract][Full Text] [Related]
9. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations. Meurette O; Lefeuvre-Orfila L; Rebillard A; Lagadic-Gossmann D; Dimanche-Boitrel MT Clin Cancer Res; 2005 Apr; 11(8):3075-83. PubMed ID: 15837763 [TBL] [Abstract][Full Text] [Related]
10. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer. Mori T; Doi R; Toyoda E; Koizumi M; Ito D; Kami K; Kida A; Masui T; Kawaguchi Y; Fujimoto K Surgery; 2005 Jul; 138(1):71-7. PubMed ID: 16003319 [TBL] [Abstract][Full Text] [Related]
11. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Ravi R; Bedi A Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014 [TBL] [Abstract][Full Text] [Related]
12. Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells. Poulaki V; Mitsiades CS; Kotoula V; Tseleni-Balafouta S; Ashkenazi A; Koutras DA; Mitsiades N Am J Pathol; 2002 Aug; 161(2):643-54. PubMed ID: 12163389 [TBL] [Abstract][Full Text] [Related]
13. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649 [TBL] [Abstract][Full Text] [Related]
14. Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Asakuma J; Sumitomo M; Asano T; Asano T; Hayakawa M Cancer Res; 2003 Mar; 63(6):1365-70. PubMed ID: 12649200 [TBL] [Abstract][Full Text] [Related]
15. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Mitsiades N; Poulaki V; Mitsiades C; Tsokos M Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151 [TBL] [Abstract][Full Text] [Related]
16. Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Kazhdan I; Marciniak RA Cancer Gene Ther; 2004 Oct; 11(10):691-8. PubMed ID: 15354201 [TBL] [Abstract][Full Text] [Related]
17. eNOS protects prostate cancer cells from TRAIL-induced apoptosis. Tong X; Li H Cancer Lett; 2004 Jul; 210(1):63-71. PubMed ID: 15172122 [TBL] [Abstract][Full Text] [Related]
18. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells. Munshi A; McDonnell TJ; Meyn RE Cancer Chemother Pharmacol; 2002 Jul; 50(1):46-52. PubMed ID: 12111111 [TBL] [Abstract][Full Text] [Related]
19. Enhanced sensitivity of bladder cancer cells to tumor necrosis factor related apoptosis inducing ligand mediated apoptosis by cisplatin and carboplatin. Mizutani Y; Nakao M; Ogawa O; Yoshida O; Bonavida B; Miki T J Urol; 2001 Jan; 165(1):263-70. PubMed ID: 11125422 [TBL] [Abstract][Full Text] [Related]
20. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Walczak H; Bouchon A; Stahl H; Krammer PH Cancer Res; 2000 Jun; 60(11):3051-7. PubMed ID: 10850456 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]